Early detection and new biomarkers are changing how we manage acute kidney injury—and its link to chronic kidney disease.

Mechanism: Sibeprenlimab is a monoclonal antibody that targets APRIL (A PRoliferation-Inducing Ligand), a key cytokine in the first hit of the pathogenic cascade. Relation to 4-Hit Cascade: By ...

ABSTRACT: Introduction: Acute renal failure (ARF) is a frequent clinico-biological syndrome in the intensive care unit. The aim of our study was to determine the prevalence of ARF in the general ...

Use of cystatin C and SGLT2 inhibitors were highlighted in the Kidney Disease: Improving Global Outcomes (KDIGO ... for patients with CKD GFR categories 3 (30-59 mL/min/1.73 m 2) to 5 (<15 ...

The company’s lead product, NEFECON, as the only in-disease IgA nephropathy (IgAN) treatment, has been included in the “KDIGO 2024 Clinical ... has generated RMB 167.3 million in sales revenue ...

KDIGO 2024 Clinical Practice Guideline for the Evaluation and ... He has been associated with Medical Dialogues for last 3 years and contributing articles on regular basis.

The Meta Quest 3 has arrived, and it's significantly more powerful than the Meta Quest 2. However, it's also twice as expensive. The Meta Quest 3 is the best VR headset — dethroning its ...

The new KDIGO CKD guideline addresses a wide range of ... defined as abnormalities of kidney structure or function persisting for more than 3 months (excluding dialysis and kidney transplantation).

In cases involving clinical presentation compatible with small-vessel vasculitis combined with positive myeloperoxidase (MPO)- or proteinase 3 (PR3)-ANCA serology, “waiting for a kidney biopsy to be ...

Eighteen patients (36.7%) developed AKI KDIGO 2 or 3; mostly KDIGO 3 (16 out of the 18 patients). Lactate level within the first six hours after ICU admission (odds ratio, OR: 1.3; 95% confidence ...